A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Latest Information Update: 05 Apr 2025
At a glance
- Drugs Xaluritamig (Primary) ; Xaluritamig (Primary) ; Abiraterone; Enzalutamide
- Indications Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 25 Mar 2025 Planned End Date changed from 17 Aug 2028 to 15 Aug 2028.
- 25 Mar 2025 Planned primary completion date changed from 15 Apr 2026 to 14 Feb 2026.
- 07 Jan 2025 Planned End Date changed from 30 Jul 2028 to 17 Aug 2028.